CoChat

ISCOMATRIX vaccines mediate CD8+ T‐cell cross‐priming by a MyD88‐dependent signaling pathway

Open access
Wilson, Nicholas S, Yang, Becky, Morelli, Adriana Baz, Koernig, Sandra, Yang, Annie, Loeser, Stefanie, Airey, Denise, Provan, Larissa, Hass, Phil, Braley, Hal, Couto, Suzana, Drane, Debbie, Boyle, Jeff, Belz, Gabrielle T, Ashkenazi, Avi, Maraskovsky, Eugene · 2012 · Immunology & Cell Biology
Cited by 101

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Generating a cytotoxic CD8+ T‐cell response that can eradicate malignant cells is the primary objective of cancer vaccine strategies. In this study we have characterized the innate and adaptive immune response to the ISCOMATRIX adjuvant, and the ability of vaccine antigens formulated with this adjuvant to promote antitumor immunity. ISCOMATRIX adjuvant led to a rapid innate immune cell response at the injection site, followed by the activation of natural killer and dendritic cells (DC) in regional draining lymph nodes. Strikingly, major histocompatibility complex (MHC) class I cross‐presentation by CD8α+ and CD8α− DCs was enhanced by up to 100‐fold when antigen was formulated with ISCOMATRIX adjuvant. These coordinated features enabled efficient CD8+ T‐cell cross‐priming, which exhibited prophylactic and therapeutic tumoricidal activity. The therapeutic efficacy of an ISCOMATRIX vaccine was further improved when co‐administered with an anti‐CD40 agonist antibody, suggesting that ISCOMATRIX‐based vaccines may combine favorably with other immune modifiers in clinical development to treat cancer. Finally, we identified a requirement for the myeloid differentiation primary response gene 88 (MyD88) adapter protein for both innate and adaptive immune responses to ISCOMATRIX vaccines in vivo. Taken together, our findings support the utility of the ISCOMATRIX adjuvant for use in the development of novel vaccines, particularly those requiring strong CD8+ T‐cell immune responses, such as therapeutic cancer vaccines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/icb.2011.71

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 101

Metadata

Authors
Wilson, N. S., Yang, B., Morelli, A. B., Koernig, S., Yang, A., Loeser, S., Airey, D., Provan, L., Hass, P., Braley, H., Couto, S., Drane, D., Boyle, J., Belz, G. T., Ashkenazi, A., & Maraskovsky, E.
Venue
Immunology & Cell Biology
Publisher
Wiley
Published
2011-09-06
Volume
90
Issue
5
Pages
540-552
ISSN
  • 0004-945X (ISSN-L)
  • 0818-9641
  • 1440-1711
OpenAlex
W2072682521
Cited by
101
References
4
FWCI
2.95
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ISCOMATRIX vaccines mediate CD8+ T‐cell cross‐priming by a MyD88‐dependent signaling pathway. https://app.cochat.ai/papers/10.1038/icb.2011.71
The paper
Wilson, N. S., Yang, B., Morelli, A. B., Koernig, S., Yang, A., Loeser, S., Airey, D., Provan, L., Hass, P., Braley, H., Couto, S., Drane, D., Boyle, J., Belz, G. T., Ashkenazi, A., & Maraskovsky, E. (2012). ISCOMATRIX vaccines mediate CD8+ T‐cell cross‐priming by a MyD88‐dependent signaling pathway. Immunology & Cell Biology. https://doi.org/10.1038/icb.2011.71

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.